New CEO for gene therapy specialist
Jörn Aldag took the helm at Amsterdam Molecular Therapies on October 5th. The company’s new Chief Executive Officer brings along 25 years of experience in corporate management and finance. As the former President and CEO of Evotec AG, Aldag was instrumental in transforming the firm from a technology provider into one of Europe’s leading drug discovery and development companies. Prof. Sander van Deventer will step down as interim-CEO of AMT, but will continue to contribute to AMT as a scientific advisor.